Biodexa Pharmaceuticals (NASDAQ: BDRX) director details ADS option stake

Rhea-AI Filing Summary

Biodexa Pharmaceuticals director Simon de Vries filed an initial ownership report showing a stock option holding. The option covers 288 American Depositary Shares with an exercise price of $475.0000 per ADS, expiring on January 23, 2034. The underlying shares vest over four years, with 25% vesting after one year and the remainder vesting quarterly, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

de Vries Simon

(Last) (First) (Middle)

C/O BIODEXA PHARMACEUTICALS PLC

1 CASPIAN POINT, CASPIAN WAY

(Street)

CARDIFF CF104DQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Biodexa Pharmaceuticals Plc [ BDRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	01/23/2034	American Depositary Shares(2)	288	$475(3)	D

Explanation of Responses:

1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

2. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.

3. The exercise price for this option is denominated in British pounds sterling at a price of GBP 373.936 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2703. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney

	/s/ Fiona Mary Powell, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Biodexa (BDRX) director Simon de Vries report on this Form 3?

He reports holding a stock option over 288 American Depositary Shares with an exercise price of $475.0000 per ADS. The filing establishes his initial beneficial ownership position as a director of Biodexa Pharmaceuticals.

What are the key terms of Simon de Vries’ Biodexa (BDRX) stock option?

The option covers 288 American Depositary Shares at an exercise price of $475.0000 per ADS and expires on January 23, 2034. It represents his right to buy ADSs at that fixed price in the future.

How does the Biodexa (BDRX) stock option reported by Simon de Vries vest?

The underlying shares vest over four years, with 25% vesting on the one-year anniversary of grant. The remaining 75% vests in 6.25% increments every three months, conditioned on his continued service through each vesting date.

What does one Biodexa (BDRX) American Depositary Share represent in this Form 3?

Each American Depositary Share represents 100,000 ordinary shares of Biodexa Pharmaceuticals, with a nominal value of PS0.000001 per ordinary share. The option therefore gives exposure to ADSs that bundle large numbers of underlying ordinary shares.

In what currency is the Biodexa (BDRX) option exercise price set for Simon de Vries?

The exercise price is denominated in British pounds at GBP 373.936 per American Depositary Share, translated in the filing to $475.0000 using a stated exchange rate. The actual obligation remains in British pounds regardless of future exchange rates.